Regulators are also reviewing Teva’s application for its Prolia biosimilar candidate. The FDA’s decisions are expected ...

Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

Artificial intelligence stands out as a particularly promising solution to the challenges of improving health literacy.

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD ...

The effects of breast cancer can remain long after the disease has left the body, serving as a traumatic daily reminder.

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

A panel of speakers demonstrated different ways technology and artificial intelligence (AI) could greatly expand access to ...

Some prior research had shown that gene therapy would not lower the amount of time children spend on ventilator support.

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...